I spoke with a pharmacist who is also in investor relations. The company has looked at the SA article that allegedly quoted Takeda and the company says the Takeda part is erroneous , that the composition is still that they can make no announcement or decision regarding the return of Omontys or the non-return until they have completely their investigations into the causality of the hypersensitivity reactions.
He said it was company policy not to give his name but said to encourage anyone on the Yahoo message boards who doubts the veracity of my report to call Takeda themselves. make sure to all Takeda in the US. The number is (877) 825-3377.
Another lie exposed.
It is awesome to hear them call you back! Very responsive company, they don't take #$%$ especially from these morons Short momos, posting non-sensical stuff.
They stirred something up, going to cost them big time, I expect it to be swift.
Sentiment: Strong Buy